BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

Pierre-Alain Ruffieux will become CEO of Lonza Group Ltd. (SIX:LONN), effective Nov. 1. He succeeds Chairman Albert Baehny, who had been serving on an interim basis since former CEO Marc Funk stepped down in January....
BioCentury | Jun 6, 2020
Product Development

Over 200 COVID-19 trials nearing completion should provide a busy summer of data readouts

Less than three months after COVID-19 reached pandemic status, and five since the virus was sequenced, drug development has reached the point where hundreds of clinical trials will soon read out. With a pile of...
BioCentury | Jun 4, 2020
Product Development

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

Newly presented Phase III data burnish GSK’s case for a regulatory submission planned for this month seeking to expand the label of lupus drug Benlysta to include lupus nephritis. Richard Furie, the lead investigator of...
BioCentury | Jun 2, 2020
Product Development

Phase I start marks first for anti-SARS-CoV-2 mAbs, first for AbCellera

A COVID-19 mAb from Eli Lilly and AbCellera has become the first against the virus to start human trials and is also the Vancouver-based company’s first product to enter the clinic. While the Phase I...
BioCentury | May 30, 2020
Politics, Policy & Law

WHO launches COVID-19 patent pool into headwinds

The World Health Organization launched its COVID-19 patent pool Friday facing significant obstacles that include a lack of support from China, the U.K. and the U.S., as well as pushback from leading pharma executives who...
BioCentury | May 29, 2020
Product Development

‘A science problem we can solve:’ a BioCentury podcast

The scientific progress toward finding countermeasures against COVID-19 in the past five months is “unprecedented in the history of the world,” GSK’s Hal Barron said on the latest BioCentury This Week - Special Report podcast . Barron,...
BioCentury | May 28, 2020
Product Development

Pharma leaders warn vaccine manufacturing doesn’t turn on a dime

Don’t expect global manufacturing capacity to rapidly fill in for the first few COVID-19 vaccines to market, according to Paul Stoffels. The J&J vice chairman and CSO said it could take over a year for...
BioCentury | May 28, 2020
Management Tracks

In new role as Flagship ‘CEO partner,’ Chouraqui to become Cellarity’s chief exec

Pharma veteran Fabrice Chouraqui is the first new hire at Flagship to take the title of CEO partner, but he likely won’t be the last. Chouraqui will join Flagship Pioneering as he also becomes CEO...
BioCentury | May 28, 2020
Finance

Fresh off Lilly deal, AbCellera readies to deploy $105M to streamline antibody-based R&D

Days after expanding a deal with Eli Lilly, AbCellera has raised $105 million in a series B round to speed its partners’ path to the clinic by expanding its own R&D capabilities. CEO Carl Hansen...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...
Items per page:
1 - 10 of 8772